FOXO4-DRI: from aging research to Cleara’s drug development
Removing certain damaged cells may help aging tissues function better. FOXO4-DRI helped test that idea in cells and mice, but human longevity benefits remain unproven. Cleara Biotech, a LongevityTech.fund portfolio company, is developing distinct candidates focused on cancer. The research shows why targeting the right cells could matter—and what it takes to turn that insight into a tested medicine.
FOXO4-DRI drew attention because it offered a way to test an idea about aging: some damaged cells keep affecting their neighbors, and removing selected cells might help the surrounding tissue work better. To understand both the opportunity and the limitations, it helps to start with the cells themselves. [1]
What are senescent cells?
A senescent cell has stopped dividing after stress or damage, yet remains alive and active. This can be useful: stopping damaged cells from multiplying helps protect the body, and senescent cells can support wound healing.
Problems can arise when these cells accumulate and persist. Some release signals that contribute to long-lasting inflammation and affect nearby tissue. Senescent cells vary, so removing them is not automatically beneficial everywhere.
Senolytics are compounds designed to selectively eliminate senescent cells. The aim is to remove harmful cells while preserving cells the body still needs. [11] [1]
How is FOXO4-DRI supposed to work?
FOXO4-DRI is an engineered peptide—a short chain of the building blocks used to make proteins. It was designed to interfere with an interaction between two proteins, FOXO4 and p53, that helped certain senescent cells survive in laboratory experiments. Disrupting that interaction triggered programmed cell death, the cell’s controlled shutdown process. The letters “DRI” describe the peptide’s engineered chemical arrangement. [1]
The molecular explanation is still being refined. A 2025 study examined how the peptide binds to p53 and found that more than one part of the peptide contributes. Such work helps researchers improve drug design; it does not yet tell us which patients would benefit. [2]
What have the studies actually shown?
The original 2017 study reported improvements in selected measures of physical function, fur condition, and kidney function in mouse experiments. It gave researchers a reason to investigate further. It did not establish longer life or better health in people. [1]
Later work makes the picture more useful—and more specific. Reducing senescent cells and improving an organ’s function are separate results. Both matter when judging whether an approach could become a treatment.
Study and setting | Finding and what it means |
|---|---|
2017 · Cells and mice | FOXO4-DRI removed selected senescent cells and improved some tissue-function measures in mice. This supported further research. [1] |
2021 · Human cartilage cells grown in a laboratory | Senescent-cell numbers fell, but subsequent cartilage formation did not improve. Clearing cells did not deliver the intended functional benefit in this experiment. [3] |
2023 · Animal models of disease in the lung’s blood vessels | Removing senescent cells, including with FOXO4-DRI, worsened pulmonary vascular outcomes in particular models. This is a warning about biological context, not a finding from treated patients. [4] |
2025 · Human scar cells and tissue studied in the laboratory | FOXO4-DRI promoted death of senescent cells in models of keloids, or overgrown scars. The study did not test treatment of patients’ scars. [10] |
2026 · Cells and mouse models of vascular aging | Researchers reported favorable changes in the aorta, the body’s main artery, and cells lining blood vessels. These findings do not establish prevention of heart attacks or other benefits in people. [5] |
The cartilage experiment illustrates a practical question: after the cells are removed, does the tissue perform better? The lung-vessel findings add another: were some of those cells helping the tissue cope with disease? The positive aortic study cannot cancel out the lung findings, because they examined different tissues and conditions. [3] [4] [5]
For readers, the useful conclusion is that the cell type, tissue, and disease determine whether removal helps. A result in human cells grown in a dish also answers a different question from a trial in people receiving treatment.
Where does Cleara fit into this story?
Cleara Biotech, a LongevityTech.fund portfolio company, is pursuing drug development around the survival mechanisms of damaged cells. Its current lead program focuses on cancer cells with impaired p53 signaling—cells in which an important damage-response system is not working normally. [6] [7]
The company identifies CL04183 as its development candidate and also describes CL04177. These have their own identities and development programs. Cleara reports activity in laboratory cancer cells, small three-dimensional tissue models, and mice. Those are company-reported findings before human clinical testing. [6]
According to Cleara’s business timeline, formal toxicology studies in rats and nonhuman primates were completed in 2025, alongside manufacturing work intended to support a clinical-trial submission. Its public pipeline places the leading program in preclinical development. [7] [8]
These steps matter because a medicine must be made consistently, reach the intended tissue, and have its risks investigated. They are progress toward testing a candidate in people. They do not establish that it is safe or effective for human use. [9]
A cancer trial would evaluate a particular candidate for a particular group of patients. Even a successful result would leave a separate question about preventing age-related disease in otherwise healthy adults.
Is FOXO4-DRI sold online the same thing?
A shared name does not establish that a product is equivalent to material used in a published experiment. Nor does it connect that product to Cleara’s distinct candidates or their manufacturing and safety work.
Three things therefore need to remain clear:
The research peptide: FOXO4-DRI as specified and prepared for a particular experiment.
The drug candidates: Cleara’s separately developed compounds, including CL04183.
An online product: a preparation whose identity, quality, and effects need evidence of their own.
Even if a product contained the intended peptide at high purity, that would not answer whether it improves health in people, at what dose, or with which risks. A purity certificate describes aspects of a sample; a clinical trial investigates what happens to patients. [9]
What would make this research useful to patients?
The next meaningful steps are a clearly identified candidate, a publicly described human study, and results that measure benefits and harms in the people the treatment is intended to help. Early trials generally begin by examining safety and how a drug behaves in the body. Later studies must establish whether it delivers a worthwhile clinical benefit. [9]
For someone following longevity science, FOXO4-DRI is a useful case study in how an exciting biological idea becomes more precise. The early mouse results opened a research direction. Later experiments showed that success depends on which cells are removed and what happens to the tissue afterward. Cleara’s development work is one route toward testing a defined medical use of related biology.
If you encounter a treatment claim, ask:
Which exact compound was tested, and is it the same as the product being discussed?
Were the results observed in cells, animals, or people?
Did patients feel or function better, and what harms were measured?
Those questions help distinguish a scientific advance from evidence that an intervention is ready to improve someone’s health.
What remains uncertain
The major gaps are human safety, effective dosing, durable benefit, and how reliably the compounds target harmful cells while sparing useful ones. Results from one tissue or disease cannot establish benefit across the body.
References
- Baar MP et al. Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Cell, 2017.
- Bourgeois B et al. The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. Nature Communications, 2025.
- Huang Y et al. Senolytic peptide FOXO4-DRI selectively removes senescent cells from in vitro expanded human chondrocytes. Frontiers in Bioengineering and Biotechnology, 2021.
- Born E et al. Eliminating senescent cells can promote pulmonary hypertension development and progression. Circulation, 2023.
- Hu Z et al. FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway. Frontiers in Bioengineering and Biotechnology, January 15, 2026.
- Cleara Biotech. Research focus and lead development candidates. Company source.
- Cleara Biotech. Business progress: investors, toxicology, and manufacturing milestones. Company source.
- Cleara Biotech. Pipeline. Company source.
- US Food and Drug Administration. The FDA’s drug review process: ensuring drugs are safe and effective.
- Kong YX et al. FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation. Communications Biology, 2025.
- National Institutes of Health. Senescent cells mapped in human body over the lifespan. July 1, 2026.
Disclosure
Cleara Biotech is a LongevityTech.fund portfolio company. This financial relationship is relevant to our coverage. Prepared with AI assistance.